Je dividenda Dermapharm Holding bezpečná?
Dermapharm Holding zvyšuje dividendu už 4 rokov.
V priebehu posledných 10 rokov Dermapharm Holding ročne 0 % znížené.
Na 5-ročnú perspektívu klesol výplata o 0 %.
Analytici očakávajú pre bežný obchodný rok nárast o Rast dividend vo výške 5,612%.
Dermapharm Holding Aktienanalyse
Čo robí Dermapharm Holding?
Dermapharm Holding SE is a German company specializing in the development, manufacturing, and distribution of pharmaceuticals and skincare products. It was founded in 1991 by Dr. Hans-Georg Feldmeier and is headquartered in Grünwald near Munich.
Dermapharm is a publicly traded company and has experienced impressive growth in recent years. It operates in the German market for prescription and over-the-counter drugs and also has a wide portfolio of skincare products for various applications.
The business model of Dermapharm focuses on the development of new pharmaceuticals and skincare products to meet the needs of patients and consumers. The company maintains a highly scientific research and development department working on innovative therapies and care products.
Dermapharm operates in various segments, including dermatological and ophthalmological therapeutics, women and children's health, urology, self-medication, and skincare. The company also offers a wide range of generic products.
Some of Dermapharm's well-known products include Acnatac, a combination of Tretinoin and Clindamycin for the treatment of acne, and the gynecological therapy product line Gynofit, which is designed for the treatment of vaginal infections and irritations in women.
Furthermore, Dermapharm has developed a comprehensive range of skincare products under its brand Linola. Linola is a brand that focuses on the care of atopic skin, neurodermatitis, and other skin conditions. Linola products are also available in various textures, including lotions, creams, and oils.
Over the years, Dermapharm has established a strong presence in the European market and operates in more than 50 countries worldwide. The company also collaborates with external partners and promoters to successfully market its brands and products.
Overall, Dermapharm has experienced strong growth thanks to its scientific approach and strong distribution network. The company remains committed to developing new therapies and products to meet the needs of patients and consumers, and to expand its presence on an international level. Dermapharm Holding je jednou z najobľúbenejších spoločností na Eulerpool.com.Investičné plány do akcií ponúkajú atraktívnu možnosť pre investorov na dlhodobú výstavbu majetku. Jednou z hlavných výhod je tzv. Cost-Average-Effekt: Pravidelnou investíciou pevnej sumy do akcií alebo do akciových fondov automaticky kupujete viac podielov, keď sú ceny nízke, a menej, keď sú vysoké. To môže viesť k výhodnejšej priemernej cene za podiel v priebehu času. Okrem toho investičné plány do akcií umožňujú aj malým investorom prístup k drahým akciám, keďže sa dá investovať už s malými sumami. Pravidelná investícia tiež podporuje disciplinovanú investičnú stratégiu a pomáha predchádzať emocionálnym rozhodnutiam, ako je impulzívne kupovanie alebo predávanie. Ďalej investorom prináša potenciálny nárast hodnoty akcií, ako aj výplaty dividend, ktoré môžu byť reinvestované, čo zvyšuje efekt zloženého úroku a tým rast investovaného kapitálu.
Akcii Dermapharm Holding je možné sporadicky nakupovať u týchto poskytovateľov: Trade Republic a Scalable Capital